ESR1 Mutated Metastatic Breast Cancer Diagnostics Market to Grow to USD 92.9M by 2035

The ESR1 mutated metastatic breast cancer diagnostics market is valued at USD 64.61 million in 2025 and is slated to reach USD 92.92 million by 2035, registering a compound annual growth rate (CAGR) of 3.7%. This growth is driven by the increasing prevalence of ESR1 mutations in metastatic breast cancer patients and the rising demand …

ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Targeting US$ 185 Million by 2033| Future Market Insights,Inc.

The market for ESR1 Mutated Metastatic Breast Cancer Diagnostics was valued at US$ 58.70 million in 2022 and is projected to grow at a CAGR of 11% to reach US$ 185 million from 2023 to 2033. The market for ESR1 mutated metastatic breast cancer diagnostics is expanding as a result of rising breast cancer incidence and the …